Annual report pursuant to Section 13 and 15(d)

INTANGIBLES - Schedule of intangible assets (Details)

v3.22.1
INTANGIBLES - Schedule of intangible assets (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Intangibles      
Total intangible assets $ 19,003 $ 19,006  
Accumulated amortization (6,451) (3,977)  
Net intangible assets 12,552 15,029 $ 7,377
Amortization expense $ 2,474 1,420  
Ceracade      
Intangibles      
Estimated Useful Lives (Years) 3 years    
Total intangible assets $ 300 300  
Luxamend      
Intangibles      
Estimated Useful Lives (Years) 3 years    
Total intangible assets $ 50 50  
Targadox      
Intangibles      
Estimated Useful Lives (Years) 3 years    
Total intangible assets $ 1,250 1,250  
Ximino      
Intangibles      
Estimated Useful Lives (Years) 7 years    
Total intangible assets $ 7,134 7,134  
Net intangible assets $ 4,671    
Exelderm      
Intangibles      
Estimated Useful Lives (Years) 3 years    
Total intangible assets $ 1,600 1,600  
Accutane      
Intangibles      
Estimated Useful Lives (Years) 5 years    
Total intangible assets $ 4,727 4,727  
Net intangible assets $ 3,939    
Anti-itch product      
Intangibles      
Estimated Useful Lives (Years) 3 years    
Total intangible assets $ 3,942 $ 3,945  
Amortization expense $ 0